Stanford Genome Technology Center has ordered a high-throughput DNA sequencing system from Pyrosequencing AB, the Company announced. The Genome Technology Center, which already uses Pyrosequencing's moderate throughput PSQ96 System for genetic analysis, has made a further commitment to the robust technology by scaling up its genotyping capacity through the Preferred Technology Program (PTP). PTP offers a fully automated high-throughput process that incorporates robotics for sample preparation. Introduced to the market by Pyrosequencing in February, the system utilizes 384-well microplates and is capable of scoring up to 100,000 SNPs per day.

The Genome Technology Center, one of the National Institutes of Health (NIH), genome centers funded since 1993 by the National Human Genome Research Institute (NHGRI), was established to increase the throughput and decrease the cost of DNA sequencing and genomic analyses and to participate in the international effort to complete the sequence of a model eukaryote, the yeast Saccharomyces cerevisiae. The yeast genome is relatively simple but shares many genes in common with the human genome making it a good system for deciphering the function of genes that might have a similar role in humans.

"It is very gratifying to know that a customer believes in Pyrosequencing technology because they know it works and then are willing to make a further commitment by scaling up their genotyping operations using the same technology," commented Erik Walldén, President and CEO of Pyrosequencing AB.

Pyrosequencing introduced the PSQ 96 System, its first DNA sequencing product, just 14 months ago and is already leading the market in both the number of systems sold and the diversity of its customer base. Designed for moderate-throughput processing, PSQ 96 System offers a scalable cost-effective solution for single nucleotide polymorphism (SNP) and other sequence analyses. The Company has currently sold more than 100 systems worldwide, across all major market segments including pharmaceutical and biotech companies as well as academic research institutions.